Adaptive Biotechnologies GAAP EPS of $0.02 beats by $0.11
Adaptive Biotechnologies (ADPT) reported Q3 GAAP EPS of $0.02, exceeding estimates by $0.11, with revenue of $83.9M, beating by $12.3M. The company raised its full-year revenue guidance for the MRD business to $276M-$286M, up from $268M previously.
How this was made
The 30-second read
Why it matters
The earnings surprise provides a short‑term catalyst for price appreciation, though long‑term performance hinges on pipeline progress.
Market read
Earnings beat offers a timely trading opportunity for ADPT, with potential spillover to the broader biotech sector.
What to watch
Guidance for the MRD business remains modest; future growth may be constrained.
Background
Adaptive Biotechnologies (ADPT) is a US‑listed biotech focused on immune profiling and diagnostics.
Ticker impact
Adaptive Biotechnologies reported Q3 GAAP EPS of $0.02, beating expectations by $0.11 and revenue of $83.9M, beating by $12.3M.
likely upward as the market prices in the earnings beat
Both EPS and revenue exceeded consensus, a rare positive surprise for a small‑cap biotech, prompting short‑covering and buying.
Market effects
Positive earnings may lift other biotech peers as investors rotate into the sector.
Limited to US biotech market; no broader regional effect.
Minimal global impact beyond biotech investors.
Counterpoint
The beat may be priced in quickly, and the stock could face profit‑taking.
Key entities
- companyAdaptive Biotechnologies
Biotech firm reporting Q3 earnings.



